Multimodal Therapy for Stage III Retinoblastoma (International Retinoblastoma Staging System): A Prospective Comparative Study

详细信息    查看全文

• 作者：Bhavna Chawla ; MS¹ ; ² ; ^{bhavna2424@hotmail.com" class="auth_mail" title="E-mail the corresponding author} ; Fahmi Hasan ; PhD¹ ; ² ; Rachna Seth ; DNB³ ; Sushmita Pathy ; MD⁴ ; Rajesh Pattebahadur ; MD¹ ; ² ; Sanjay Sharma ; MD⁵ ; Ashish Upadhyaya ; MA⁶ ; Rajvardhan Azad ; MD¹ ; ²
• 关键词：CI ; confidence interval ; EBRT ; external-beam radiotherapy ; IRSS ; International Retinoblastoma Staging System ; Mesna ; 2-mercaptoethane sulfonate Na ; MRI ; magnetic resonance imaging ; NAC ; neoadjuvant chemotherapy ; SD ; standard deviation ; VEC ; vincristine ; etoposide ; and carboplatin
• 刊名：Ophthalmology
• 出版年：2016
• 出版时间：September 2016
• 年：2016
• 卷：123
• 期：9
• 页码：1933-1939
• 全文大小：744 K

文摘

To compare the efficacy of 2 chemotherapeutic drug combinations as part of multimodal therapy for orbital retinoblastoma.

Design

Prospective, comparative, study.

Participants

Patients with stage III retinoblastoma (International Retinoblastoma Staging System).

Methods

Demographic and clinical features were recorded at presentation. Treatment consisted of a multimodal protocol with neoadjuvant chemotherapy, enucleation, orbital external-beam radiotherapy, and adjuvant chemotherapy. For chemotherapy, patients were randomized into 2 groups: group A patients were treated with vincristine, etoposide, and carboplatin (VEC) and group B patients were treated with carboplatin and etoposide, alternating with cyclophosphamide, idarubicin, and vincristine. Treatment outcomes and adverse effects were recorded. Efficacy parameters were compared between the groups.

Main Outcome Measures

Survival probability, cause of death, and chemotherapy-related toxicity.

Results

A total of 54 children were recruited (27 in each group). The mean ± SD follow-up was 21.3±11.34 months. The overall Kaplan-Meier survival probability was 80% (95% confidence interval [CI], 0.67–0.89) and 42% (95% CI, 0.24–0.59) at 1 year and 4 years, respectively. There were 9 deaths in group A and 15 deaths in group B. The Kaplan-Meier survival probability at 1 year was similar between the groups: 81% (95% CI, 0.60–0.91) and 79% (95% CI, 0.58–0.9) for groups A and B, respectively. At 4 years, the survival probability for group A was higher (63% [95% CI, 0.41–0.79] vs. 25% [95% CI, 0.08–0.46] for groups A and B, respectively), with a strong trend of better survival in group A over time (P = 0.05). The major cause of death was central nervous system relapse (8 patients in group A and 7 patients in group B). Two patients in group B died of sepsis after febrile neutropenia. Grade 3 and grade 4 hematologic toxicities were more common in group B, with a significant difference in grade 4 neutropenia (P = 0.002).

Conclusions

This study compared the outcomes of VEC chemotherapy with a 5-drug combination of vincristine and carboplatin, alternating with cyclophosphamide, idarubicin, and vincristine, for stage III retinoblastoma. The VEC combination was found to be more effective and may be recommended as neoadjuvant and adjuvant chemotherapy.